Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: jackie who wrote (10726)	7/11/1999 11:13:00 AM
From: aknahow	Respond to of 17367

Could not be certain you understood that this comment was Castellos, not mine. <<< "It's a legitimate question to ask "How many little pieces of pie do we have to cut to demonstrate the product works before it can be used for the whole circle?" That's yet to be seen. But as you can see by the indications shown, we are gradually going around the circle. Its a long process, but one that gives us a better possibility of winning in the end, instead of trying to get it all in one bite.">> Xoma indeed is doing little pieces of the pie. The Trauma trial is not a sepsis trial. Allergans future trials if any, will be another small slice, CF, liver, etc. But XOMA is aware that if the small pieces demonstrate positive results, what you indicate will kick in and they may end up having to do as many slices. But at the present time I don't think one can say they won't need to do more slices.